Economic Evaluation of Ulipristal Acetate For The Treatment of Patients With Moderate And Severe Symptoms of Uterine Fibroids Before Surgery In Mexico

Paladio-Hernández, Já; Rosas, Reinaldo; Pozo, L; Cid, O Del; Robles_Valencia, JA

doi:10.1016/j.jval.2015.09.337

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A similar study was conducted in Mexico, concluding that UPA is a cost-effective alternative to surgery, as 21% of the patients treated with UPA avoided hysterectomy, which translates to $47,614,017 USD being saved for every 1000 patients. [ 144 ].…”

Section: Treatment Options For Uterine Fibroidsmentioning

confidence: 99%

Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids†

Ali

Al-Hendy

2017

Biology of Reproduction

View full text Add to dashboard Cite

Uterine fibroids (UFs, AKA leiomyoma) are the most important benign neoplastic threat to women's health, with costs up to hundreds of billions of health care dollars worldwide. Uterine fibroids caused morbidities exert a tremendous health toll, impacting the quality of life of women of all ethnicities, especially women of color. Clinical presentations include heavy vaginal bleeding, pelvic pain, bulk symptoms, subfertility, and obstetric complications. Current management strategies heavily lean toward surgical procedures; nonetheless, the choice of treatment is generally subject to patient's age and her desire to preserve future fertility. Women with UF who desire to maintain future fertility potential face a dilemma because of the limited treatment choices that are currently available to help them achieve that goal. Recently, ulipristal acetate the first of the promising family of oral selective progesterone receptor modulators has been approved for UF treatment in Europe, Canada, and several other countries and is under review for possible approval in the USA. In this review article, we discuss recent advances in the management options against UF with a bend toward oral effective long-term treatment alternatives who are particularly suited for those seeking to preserve their future fertility potential. We also explore the transformative concept of primary and secondary UF prevention using these new anti-UF agents. We envision a remarkable shift in the management of UF in future years from surgical/invasive treatment to orally administrated options; clearly, this potential shift will require additional intense clinical research.

show abstract

Section: Treatment Options For Uterine Fibroidsmentioning

confidence: 99%